4 April 2017

Shield Therapeutics plc - Preliminary Results for the Year Ended 31 December 2016 


London, UK, 4 April 2017. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical Company focused on secondary care, today announces its preliminary Group results for the year ended 31 December 2016.

Highlights (including post period-end)


  • Marketing authorisation achieved across the EU for Feraccruwith first sales recorded in the UK and Germany
  • Feraccru achieved attractive price points in the UK and Germany
  • Approximately 20 customer-facing members of the team now interacting daily with customers in the UK and
  • Germany, with our sales teams expanding further through 2017
  • First commercial product shipments completed to our Central & East European commercialisation partner, AOP Orphan Pharmaceuticals
  • New Composition of Matter patent granted for Feraccru, extending the protection to mid-2030s
  • AEGIS-H2H and AEGIS-CKD Phase 3 studies progressing well with data anticipated towards the end of 2017 and positive data expected to facilitate broader commercialisation in Europe and NDA filing in the USA
  • Positive discussions with further licensing partners for Feraccru in non-core markets
  • PT20 and PT40 activities on-going


  • Successful completion of an initial public offering (IPO) on AIM of the London Stock Exchange in February 2016, raising £32.5 million (gross) and further potential gross proceeds of £17.5 million, subject to Warrants exercise
  • First commercial revenues of £304,000 recorded, representing initial supplies of Feraccru into the distribution channel
  • Net loss for FY2016 of £15.0 million (2015: £23.6 million) on IFRS basis; EPS loss of £0.15 per share (2015: £0.57)
  • Adjusted net loss for FY2016, excluding the impact of exceptional items, of £9.4 million (2015: £5.3 million); EPS loss of £0.09 (2015: £0.13)
  • Year-end net cash of £21.0 million (2015: £0.7 million)


  • Joanne Estell will join the Group as Chief Financial Officer and Board member on 1 May 2017 – see separate announcement issued today

“2016 was a transformational year for Shield as we became a listed and increasingly commercially focused organisation. Shield is now actively generating revenue from its lead product, Feraccru, and, across its pipeline, has the opportunity to create operational leverage and access large markets with significant unmet medical needs. With the competencies added through 2016, Shield is now well positioned to continue on our path to becoming a profitable international specialty pharmaceutical company and the management team and Board have great confidence and ambitions for the future.”

Carl Sterritt

Chief Executive Officer of Shield Therapeutics plc

Webcast and conference call for analysts

A briefing for analysts will be held at 9.30am BST on 4 April 2017 in the Guildhall Room at 85 Gresham Street, London EC2V 7NQ. There will be a simultaneous webcast and live conference call with Q&A and the presentation and access to the webcast will be on Shield’s website at www.shieldtherapeutics.com.

Dial in details:

Participant local dial-in: +44(0)20 3427 1909

Participant free phone dial-in: 0800 279 5736

Participant code: 3378780

An audio replay file will be made available shortly afterwards via the Company website: shieldtherapeutics.com 

For further information please contact:

Shield Therapeutics plc
+44 (0)207 186 8500
Carl Sterritt, Chief Executive Officer

+44 (0)203 100 2222
Liberum Capital Limited
Christopher Britton/Steve Pearce

Financial PR Advisor
Consilium Strategic Communications
+44 (0)203 709 5700
Mary-Jane Elliott/Matthew Neal/Lindsey Neville/Hendrik Thys 

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030’s. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtherapeutics.com.


This announcement contains inside information for the purposes of the Market Abuse Regulation.

*** Please see attached pdf document for full results statement ***

download pdf

Back to previous page